Device for easier access to dialysis through arteriovenous fistulas

A Study to Evaluate the Safety and Effectiveness of Voyager's Access Device for Patients Undergoing Routine Hemodialysis (Access Cannulation Trial II)

This study is testing a new device called VenaSure to see if it can make it easier and safer for people on hemodialysis to access their arteriovenous fistulas.

Quick facts

• Phase: NA
• Study type: Interventional
• Enrollment: 100 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Voyager Biomedical (industry)
• Locations: 8 sites (Dothan, Alabama and 7 other locations)
• Trial ID: NCT05490225 on ClinicalTrials.gov

What this trial studies

This clinical investigation aims to evaluate the safety and efficacy of a device called VenaSure for cannulating arteriovenous fistulas (AVFs) in patients undergoing hemodialysis. It is a multi-site, open-label, single-arm study that will last approximately 48-60 months, including a 6-week healing observation period post-implantation and 36 months of monitoring during routine dialysis. The study focuses on patients whose AVFs are difficult to cannulate due to depth or other complications, with the goal of supporting FDA clearance for the device.

Who should consider this trial

Good fit: Ideal candidates are patients with arteriovenous fistulas that are difficult to cannulate due to depth or previous failed attempts.

Not a fit: Patients with easily accessible arteriovenous fistulas or those who do not require hemodialysis may not benefit from this study.

Why it matters

Potential benefit: If successful, this device could significantly improve access to dialysis for patients with challenging vascular access.

How similar studies have performed: While this approach is innovative, similar studies have shown promise in improving vascular access for dialysis patients.

Eligibility criteria

Inclusion:

1. The subject's AVF is deemed uncannulatable because:

   1. The subject's anticipated cannulation zone(s) is/are \>6mm in depth from the surface of the skin to the anterior wall of the access vein as confirmed by ultrasound within 8 weeks prior to device implantation (each zone, Arterial/Pull and Venous/Push, shall be assessed independently of one another for device placement):

      * Arterial/Pull Zone: \_\_\_\_\_ mm deep
      * Venous/Push Zone: \_\_\_\_\_ mm deep

      OR
   2. The subject's dialysis unit (which includes an experienced cannulator) attests that repeated cannulation is not achievable in their clinic due to one of the following:

      * Failed access attempt in a fistula that was previously approved for cannulation, or
      * Unable to palpate the fistula such that cannulation is not possible without patient risk.
2. The access surgeon caring for the subject attests that the device is likely to be at least equivalent to other methods (such as venous transposition or suction-assisted lipectomy) that could make the AVF easier to access and reduce risk of cannulation infiltrations.
3. The subject has either a radio-cephalic, brachio-cephalic or transposed brachio-basilic fistula.

Exclusion:

1. The subject's access vein is \>15mm in depth at either cannulation zones as measured by ultrasound within 8 weeks prior to device implantation.

   * Arterial/Pull Zone: \_\_\_\_\_ mm in depth
   * Venous/Push Zone: \_\_\_\_\_ mm in depth Note: these values should match inclusion criteria #1
2. Both bidimensional measurements in the subject's access vein have a diameter of \<4mm, taken with a tourniquet in place or through manual compression to the outflow, as measured by ultrasound within 8 weeks prior to device implantation (cannulation zone specific - one zone does not affect the other's eligibility).

   * Arterial/Pull Zone: \_\_\_\_\_ x \_\_\_\_\_ mm in diameter
   * Venous/Push Zone: \_\_\_\_\_ x \_\_\_\_\_ mm in diameter
3. The subject has a flow rate of \<550mL/min in the inflow artery proximal to the arterial anastomosis as measured by ultrasound within 8 weeks prior to device implantation.

   • Flow: \_\_\_\_\_ mL/min
4. The subject does NOT have a prescription to receive maintenance hemodialysis at least 2 times per week.
5. The subject's life expectancy is \<1 year per the Investigator.
6. The subject does NOT have a signed and dated consent form.
7. The AVF is a non-transposed basilic or brachial vein outflow AVF.
8. The subject has high flow rates placing them at risk for heart failure and death at the discretion of the Investigator.
9. The subject has a known skin infection, hypersensitive skin, skin breakdown/erosion or skin allergies at the potential implant sites.
10. The subject has a known active systemic infection or positive blood cultures present.
11. The subject's AVF has undergone a major revision and at the discretion of the Investigator can impact fistula viability and device placement (such as DRIL or PTFE segment insertion, banding, aneurysm repair, etc.), or the subject has had an occurrence of and/or intervention for AV access stenosis or thrombosis within the past month (excluded to avoid unnecessary placement into an AVF with a high likelihood of failure).
12. The subject is \<18 years of age.
13. The subject plans to become pregnant prior to their potential treatment date.
14. The subject has a body mass index \>50kg/m2.
15. The subject has a known clinically significant bleeding or coagulation disorder, including but not limited to low platelet count (\<50,000), hypercoagulable state (e.g., antithrombin IE deficiency, antiphospholipid or anticardiolipin antibodies, Factor V Leiden, circulating Lupus anticoagulant, current, heparin-induced thrombocytopenia, protein C or S deficiency, history of recurrent deep vein thrombosis not related to AV access).
16. The subject has an active malignancy.
17. The subject has a known or suspected allergy to titanium, aluminum, or vanadium.
18. The subject has had a significant cardiovascular event/intervention that makes them a poor surgical candidate such as myocardial infarction, angioplasty, or stent placement within 3 months of implantation.
19. The subject has had a significant peripheral vascular disease requiring a major intervention within the previous 12 months (in the target limb).
20. The subject has had a significant neurovascular event such as stroke or major intervention within the previous 12 months.
21. The subject has an uncontrolled major symptomatic medical problem per the Investigator.
22. The subject has a likelihood of poor protocol compliance due to mental incapacity, an inability to understand treatment instructions, or for any other reason in the opinion of the Investigator.
23. The subject is currently participating in another investigational drug or device investigation that could clinically interfere with the endpoints of this investigation.
24. The subject's conversion to home hemodialysis is anticipated at any point during their foreseeable participation in this investigation.

Where this trial is running

Dothan, Alabama and 7 other locations

• Trinity Research Group — Dothan, Alabama, United States (RECRUITING)
• Apex Research — Riverside, California, United States (RECRUITING)
• Brigham and Women's Hospital — Boston, Massachusetts, United States (RECRUITING)
• Northwell Health — Hyde Park, New York, United States (RECRUITING)
• MUSC Health Orangeburg — Orangeburg, South Carolina, United States (RECRUITING)
• Cardiothoracic and Vascular Surgeons — Austin, Texas, United States (RECRUITING)
• Baylor Scott & White — Dallas, Texas, United States (RECRUITING)
• Fairlawn Surgery Center — Roanoke, Virginia, United States (RECRUITING)

Study contacts

• Principal investigator: Stephen Hohmann, MD — Baylor Scott and White Health
• Study coordinator: Britnee Ochabski

Conditions: Dialysis, Complications, Vascular Access Complication